Replies to post #74 on Celsion Corporation (CLSN)

[cash2go]

SHARP trial was halted early for approval

The placebo-controlled trial conducted in Spain 603 patients

median overall survival of 10.7 months for sorafenib and 7.9 months for placebo
median time to progression of 24 weeks for sorafenib and 12 weeks for placebo

http://www.medscape.com/viewarticle/576128